# Regeneron Pharmaceuticals, Inc.: financial statements, quarterly

REGN · Nasdaq · CIK 872589 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/regn.md) · [Financials](/companies/regn/financials.md) · [Filings](/companies/regn/filings.md) · [Insiders](/companies/regn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/regn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,363](/filings/0001804220-24-000040.md) | [3,434 d](/filings/0000872589-26-000008.md) | [3,145](/filings/0001804220-25-000022.md) | [3,547](/filings/0000872589-25-000019.md) | [3,721](/filings/0000872589-25-000028.md) | [3,789 d](/filings/0000872589-26-000008.md) | [3,029](/filings/0000872589-26-000016.md) | [3,676](/filings/0000872589-26-000025.md) | [3,754](/filings/0000872589-25-000028.md) | [3,884 d](/filings/0000872589-26-000008.md) | [3,605](/filings/0000872589-26-000016.md) | [4,291](/filings/0000872589-26-000025.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1,075](/filings/0001804220-24-000040.md) | [1,177 d](/filings/0000872589-26-000008.md) | [1,248](/filings/0001804220-25-000022.md) | [1,200](/filings/0000872589-25-000019.md) | [1,272](/filings/0000872589-25-000028.md) | [1,412 d](/filings/0000872589-26-000008.md) | [1,327](/filings/0000872589-26-000016.md) | [1,422](/filings/0000872589-26-000025.md) | [1,475](/filings/0000872589-25-000028.md) | [1,626 d](/filings/0000872589-26-000008.md) | [1,544](/filings/0000872589-26-000016.md) | [1,632](/filings/0000872589-26-000025.md) |
| Selling, general and administrative | $m | [641](/filings/0001804220-24-000040.md) | [738 d](/filings/0000872589-26-000008.md) | [689](/filings/0001804220-25-000022.md) | [759](/filings/0000872589-25-000019.md) | [714](/filings/0000872589-25-000028.md) | [792 d](/filings/0000872589-26-000008.md) | [633](/filings/0000872589-26-000016.md) | [634](/filings/0000872589-26-000025.md) | [658](/filings/0000872589-25-000028.md) | [775 d](/filings/0000872589-26-000008.md) | [648](/filings/0000872589-26-000016.md) | [662](/filings/0000872589-26-000025.md) |
| Operating income | $m | [1,111](/filings/0001804220-24-000040.md) | [973 d](/filings/0000872589-26-000008.md) | [751](/filings/0001804220-25-000022.md) | [1,070](/filings/0000872589-25-000019.md) | [1,180](/filings/0000872589-25-000028.md) | [990 d](/filings/0000872589-26-000008.md) | [592](/filings/0000872589-26-000016.md) | [1,080](/filings/0000872589-26-000025.md) | [1,027](/filings/0000872589-25-000028.md) | [880 d](/filings/0000872589-26-000008.md) | [643](/filings/0000872589-26-000016.md) | [1,294](/filings/0000872589-26-000025.md) |
| Interest expense | $m | [17.8](/filings/0001804220-23-000031.md) | [18.3 d](/filings/0001804220-24-000009.md) | [16.1](/filings/0001804220-24-000017.md) | [14.8](/filings/0000872589-25-000019.md) | [13.8](/filings/0000872589-25-000028.md) | [10.5 d](/filings/0000872589-26-000008.md) | [8.7](/filings/0000872589-26-000016.md) | [3.6](/filings/0000872589-26-000025.md) | [19.3](/filings/0000872589-25-000028.md) | [12.2 d](/filings/0000872589-26-000008.md) | [12.9](/filings/0000872589-26-000016.md) | [11.0](/filings/0000872589-26-000025.md) |
| Income tax | $m | [103](/filings/0001804220-24-000040.md) | [(12.0) d](/filings/0000872589-26-000008.md) | [(21.3)](/filings/0001804220-25-000022.md) | [196](/filings/0000872589-25-000019.md) | [152](/filings/0000872589-25-000028.md) | [40.4 d](/filings/0000872589-26-000008.md) | [96.3](/filings/0000872589-26-000016.md) | [127](/filings/0000872589-26-000025.md) | [303](/filings/0000872589-25-000028.md) | [199 d](/filings/0000872589-26-000008.md) | [104](/filings/0000872589-26-000016.md) | [231](/filings/0000872589-26-000025.md) |
| Net income | $m | [1,008](/filings/0001804220-24-000040.md) | [1,160 d](/filings/0000872589-26-000008.md) | [722](/filings/0000872589-25-000028.md) | [1,432](/filings/0000872589-25-000028.md) | [1,341](/filings/0000872589-25-000028.md) | [918 d](/filings/0000872589-26-000008.md) | [809](/filings/0000872589-26-000025.md) | [1,392](/filings/0000872589-26-000025.md) | [1,460](/filings/0000872589-25-000028.md) | [845 d](/filings/0000872589-26-000008.md) | [727](/filings/0000872589-26-000025.md) | [1,297](/filings/0000872589-26-000025.md) |
| Diluted EPS | $ per share | [8.89](/filings/0001804220-24-000040.md) | not reported | [6.27](/filings/0001804220-25-000022.md) | [12.41](/filings/0000872589-25-000019.md) | [11.54](/filings/0000872589-25-000028.md) | not reported | [7.27](/filings/0000872589-26-000016.md) | [12.81](/filings/0000872589-26-000025.md) | [13.62](/filings/0000872589-25-000028.md) | not reported | [6.75](/filings/0000872589-26-000016.md) | [12.23](/filings/0000872589-26-000025.md) |
| Basic EPS | $ per share | [9.48](/filings/0001804220-24-000040.md) | not reported | [6.70](/filings/0001804220-25-000022.md) | [13.25](/filings/0000872589-25-000019.md) | [12.40](/filings/0000872589-25-000028.md) | not reported | [7.58](/filings/0000872589-26-000016.md) | [13.24](/filings/0000872589-26-000025.md) | [14.09](/filings/0000872589-25-000028.md) | not reported | [6.99](/filings/0000872589-26-000016.md) | [12.62](/filings/0000872589-26-000025.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.2](/filings/0001804220-24-000040.md) | [2.7](/filings/0000872589-26-000008.md) | [2.6](/filings/0001804220-25-000022.md) | [1.9](/filings/0000872589-25-000019.md) | [2.0](/filings/0000872589-25-000028.md) | [2.5](/filings/0000872589-26-000008.md) | [3.1](/filings/0000872589-26-000016.md) | [2.0](/filings/0000872589-26-000025.md) | [2.5](/filings/0000872589-25-000028.md) | [3.1](/filings/0000872589-26-000025.md) | [3.0](/filings/0000872589-26-000016.md) | [2.5](/filings/0000872589-26-000025.md) |
| Current assets | $bn | [18.6](/filings/0001804220-23-000031.md) | [19.5](/filings/0001804220-25-000011.md) | [18.9](/filings/0001804220-24-000017.md) | [19.1](/filings/0001804220-24-000028.md) | [19.3](/filings/0001804220-24-000040.md) | [18.7](/filings/0000872589-26-000008.md) | [17.6](/filings/0001804220-25-000022.md) | [16.9](/filings/0000872589-25-000019.md) | [18.0](/filings/0000872589-25-000028.md) | [18.0](/filings/0000872589-26-000025.md) | [18.2](/filings/0000872589-26-000016.md) | [18.4](/filings/0000872589-26-000025.md) |
| Total assets | $bn | [32.2](/filings/0001804220-23-000031.md) | [33.1](/filings/0001804220-25-000011.md) | [34.4](/filings/0001804220-24-000017.md) | [36.1](/filings/0001804220-24-000028.md) | [37.4](/filings/0001804220-24-000040.md) | [37.8](/filings/0000872589-26-000008.md) | [37.5](/filings/0001804220-25-000022.md) | [38.2](/filings/0000872589-25-000019.md) | [40.2](/filings/0000872589-25-000028.md) | [40.6](/filings/0000872589-26-000025.md) | [40.9](/filings/0000872589-26-000016.md) | [41.7](/filings/0000872589-26-000025.md) |
| Current liabilities | $bn | [3.6](/filings/0001804220-23-000031.md) | [3.4](/filings/0001804220-25-000011.md) | [3.6](/filings/0001804220-24-000017.md) | [3.5](/filings/0001804220-24-000028.md) | [3.7](/filings/0001804220-24-000040.md) | [3.9](/filings/0000872589-26-000008.md) | [3.6](/filings/0001804220-25-000022.md) | [3.7](/filings/0000872589-25-000019.md) | [4.4](/filings/0000872589-25-000028.md) | [4.4](/filings/0000872589-26-000025.md) | [5.1](/filings/0000872589-26-000016.md) | [5.5](/filings/0000872589-26-000025.md) |
| Total liabilities | $bn | [7.3](/filings/0001804220-23-000031.md) | [7.1](/filings/0001804220-25-000011.md) | [7.4](/filings/0001804220-24-000017.md) | [7.9](/filings/0001804220-24-000028.md) | [8.1](/filings/0001804220-24-000040.md) | [8.4](/filings/0000872589-26-000008.md) | [8.2](/filings/0001804220-25-000022.md) | [8.3](/filings/0000872589-25-000019.md) | [9.2](/filings/0000872589-25-000028.md) | [9.3](/filings/0000872589-26-000025.md) | [9.4](/filings/0000872589-26-000016.md) | [10.0](/filings/0000872589-26-000025.md) |
| Long-term debt | $bn | [2.0](/filings/0001804220-23-000031.md) | [2.0](/filings/0001804220-25-000011.md) | [2.0](/filings/0001804220-24-000017.md) | [2.0](/filings/0001804220-24-000028.md) | [2.0](/filings/0001804220-24-000040.md) | [2.0](/filings/0000872589-26-000008.md) | [2.0](/filings/0001804220-25-000022.md) | [2.0](/filings/0000872589-25-000019.md) | [2.0](/filings/0000872589-25-000028.md) | [2.0](/filings/0000872589-26-000025.md) | [2.0](/filings/0000872589-26-000016.md) | [2.0](/filings/0000872589-26-000025.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [24.9](/filings/0001804220-24-000040.md) | [26.0](/filings/0000872589-26-000008.md) | [27.0](/filings/0000872589-25-000028.md) | [28.2](/filings/0000872589-25-000028.md) | [29.3](/filings/0000872589-25-000028.md) | [29.4](/filings/0000872589-26-000025.md) | [29.4](/filings/0000872589-26-000025.md) | [29.9](/filings/0000872589-26-000025.md) | [31.0](/filings/0000872589-25-000028.md) | [31.3](/filings/0000872589-26-000025.md) | [31.4](/filings/0000872589-26-000025.md) | [31.7](/filings/0000872589-26-000025.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,114 d](/filings/0001804220-24-000040.md) | [1,090 d](/filings/0000872589-26-000008.md) | [1,513](/filings/0001804220-25-000022.md) | [354 d](/filings/0000872589-25-000019.md) | [1,291 d](/filings/0000872589-25-000028.md) | [1,263 d](/filings/0000872589-26-000008.md) | [1,045](/filings/0000872589-26-000016.md) | [1,144 d](/filings/0000872589-26-000025.md) | [1,619 d](/filings/0000872589-25-000028.md) | [1,171 d](/filings/0000872589-26-000008.md) | [1,079](/filings/0000872589-26-000016.md) | [813 d](/filings/0000872589-26-000025.md) |
| Capital expenditure | $m | [176 d](/filings/0001804220-24-000040.md) | [251 d](/filings/0000872589-26-000008.md) | [134](/filings/0001804220-25-000022.md) | [181 d](/filings/0000872589-25-000019.md) | [242 d](/filings/0000872589-25-000028.md) | [200 d](/filings/0000872589-26-000008.md) | [229](/filings/0000872589-26-000016.md) | [219 d](/filings/0000872589-26-000025.md) | [201 d](/filings/0000872589-25-000028.md) | [249 d](/filings/0000872589-26-000008.md) | [231](/filings/0000872589-26-000016.md) | [240 d](/filings/0000872589-26-000025.md) |
| Dividends paid | $m | not reported | not reported | [0.0](/filings/0001804220-25-000022.md) | [0.0 d](/filings/0000872589-25-000019.md) | [0.0 d](/filings/0000872589-25-000028.md) | [0.0 d](/filings/0000872589-26-000008.md) | [93.8](/filings/0000872589-26-000016.md) | [92.6 d](/filings/0000872589-26-000025.md) | [91.2 d](/filings/0000872589-25-000028.md) | [92.7 d](/filings/0000872589-26-000008.md) | [97.8](/filings/0000872589-26-000016.md) | [96.8 d](/filings/0000872589-26-000025.md) |
| Share repurchases | $m | [547 d](/filings/0001804220-24-000040.md) | [289 d](/filings/0000872589-26-000008.md) | [291](/filings/0001804220-25-000022.md) | [604 d](/filings/0000872589-25-000019.md) | [735 d](/filings/0000872589-25-000028.md) | [973 d](/filings/0000872589-26-000008.md) | [1,041](/filings/0000872589-26-000016.md) | [1,062 d](/filings/0000872589-26-000025.md) | [664 d](/filings/0000872589-25-000028.md) | [672 d](/filings/0000872589-26-000008.md) | [794](/filings/0000872589-26-000016.md) | [1,169 d](/filings/0000872589-26-000025.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [113](/filings/0001804220-23-000031.md) | [114](/filings/0001804220-24-000017.md) | [114](/filings/0001804220-24-000028.md) | [113](/filings/0001804220-24-000040.md) | [115](/filings/0001804220-25-000022.md) | [115](/filings/0000872589-25-000019.md) | [116](/filings/0000872589-25-000028.md) | [111](/filings/0000872589-26-000016.md) | [109](/filings/0000872589-26-000025.md) | [107](/filings/0000872589-25-000028.md) | [108](/filings/0000872589-26-000016.md) | [106](/filings/0000872589-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 93,955,110 at 2012-07-13, from the cover of the [10-Q filed 2012-07-25](/filings/0001206774-12-003062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.